Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.42 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.42 |
| ▸ | CNR1 | P21554 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1705734 | 0.95 | CNR2 (0.44) | CNR2TAS2R14CNR1LMNATSHR | |
| SCHEMBL30701971 | 0.87 | CNR2 (0.46) | CNR2TAS2R14CNR1LMNATSHR | |
| SCHEMBL27192066 | 0.87 | CNR2 (0.46) | CNR2TAS2R14CNR1LMNATSHR | |
| SCHEMBL30609120 | 0.84 | CNR2 (0.43) | CNR2TAS2R14CNR1LMNATSHR | |
| SCHEMBL12205672 | 0.84 | CNR2 (0.56) | CNR2TAS2R14CNR1BACE1MAPT | |
| SCHEMBL1705206 | 0.83 | CNR2 (0.60) | CNR2TAS2R14CNR1LMNATSHR | |
| SCHEMBL1411474 | 0.82 | CNR2 (0.50) | CNR2TAS2R14CNR1LMNATSHR | |
| SCHEMBL30701970 | 0.82 | CNR2 (0.50) | CNR2TAS2R14CNR1LMNATSHR | |
| SCHEMBL29407317 | 0.82 | CNR2 (0.43) | CNR2TAS2R14CNR1LMNATSHR | |
| SCHEMBL1571343 | 0.82 | CNR2 (0.43) | CNR2TAS2R14CNR1LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| EP-2313374-B1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-05-02 | — | — | US | disclosed |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-05-02 | — | — | US | disclosed |
| US-8399482-B2 | 6-substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| US-8399482-B2 | 6-substituted isoquinolines and isoquinolinones | SANOFI (FR) | 2013-03-19 | — | — | US | disclosed |
| US-20110190339-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190339-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| WO-2009156100-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
| WO-2009156099-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | ROCK1, MYLK, ROCK2 | CNR2 4689/4885TAS2R14 4862/4885CNR1 4561/4885 |
| US-20110190339-A1 | 6-SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES | MYLK2, MYLK, MYLK3 | CNR2 4535/4885TAS2R14 4848/4885CNR1 4413/4885 |
| US-20130109715-A1 | 6-Substituted isoquinolines and isoquinolinones | MYLK2, MYLK, MYLK3 | CNR2 4751/4885TAS2R14 4652/4885CNR1 4618/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.